Dr. SHREYANGSI BISWAS

Dr.Kalishankar Das

Abstract

AIM:TO SEE OUTCOME OF INTRAVITREAL RANIBIZUMAB MONOTHERAPY [MT] IN APROP

METHOD: AN INTERVENTIONAL STUDY DONE AT TERTIARY HEALTH CARE IN EASTERN INDIA.12 PRETERM INFANTS [22 EYES] OF APROP WHO GIVEN RANIBIZUMAB AS MT WERE INCLUDED.MEAN GA WAS 28.3 WKS.THEY DID REGULAR F/U & DETAILED EXAM WAS DONE BY SINGLE OBSERVER.

RESULT:OUT OF 22 EYES,ONLY 4 EYES HAD COMPLETE REGRESSION WITH COMPLETE VASCULARISATION [18.2%]. 6 EYES AFTER 1ST INJ HAD REGRESSION WITH INCOMPLETE REVASCULARISATION AFTER 45 WEEKS PMA[ 27.3%] & NEEDED LASER PHOTOCOAGULATION [LPC]. 12 EYES HAD RECURRENCE 6-8 WEEKS AFTER 1ST INJ [54.54%].OUT OF THEM, 4 HAD PARTIAL REGRESSION BUT PRESENSE OF PLUS DISEASE [33.33%].REST 8 HAD COMPLETE REGRESSION BUT INCOMPLETELY VASCULARISED AFTER 45 WK OF PMA [66.67%]. THEY REQUIRED LPC.

CONCLUSION:INJ RANIBIZUMAB IS CONSIDERED SAFE FOR INFANTS OF LOWER GA & BIRTH WT.IT STILL REMAIN CONTROVERSIAL FOR USAGE AS MT IN APROP AS 81.84% REQUIRED LPC AFTER 2ND INJ 6-8 WKS AFTER 1ST DOSE

Full Text